Investor Relations (IR) Questions: Theragenics Corp TGX
Click here to return to the biotech IRQ Index
Answers received: October 2012
1) When is the last time TGX raised cash through an offering (diluted)?
We haven’t raised any cash since 2nd IPO in 1989
2) How much cash (not cash equivalents) does TGX have?
We report cash and cash equivalents and our 3rd quarter cash and equivalents (at September 30) will be shown in the 10-Q which will be issued by the middle of November. SEC filings can be found on our website www.theragenics.com in the Investor Relations section or the SEC’s website.
3) What and approximately when is the next known catalyst?
We will have an earnings call, most likely the week of 11/8, if you would like to listen in to hear management speak on strategy and the marketplace.
4) What is TGX's quarterly cash burn?
Our 3rd quarter earnings release, 10Q with cash flow statement should provide insight on cash used.
5) Does TGX have an existing line of credit and if so how much can they draw against it?
We just renewed our line of credit, press release is below.
PRESS RELEASE: Theragenics(R) Renews Credit Agreement
(Dow Jones and Company, Inc.) Oct 11 07:16 AM EDT
Available Borrowings Increased to $40 Million Under Amended and Restated Credit Agreement BUFORD, Ga.--(BUSINESS WIRE)--October 11, 2012--
Theragenics Corporation (NYSE: TGX), a medical device company serving the surgical products and prostate cancer treatment markets, today announced that it has entered into a Second Amended and Restated Credit Agreement with Wells Fargo Bank, National Association. The new three year credit agreement, which is unsecured, replaces the $30 million credit agreement with Wells Fargo that was set to expire on October 31, 2012. Borrowings of$22 million that were outstanding under the old credit agreement have been refinanced under the new $ 40 million credit agreement. The interest rate on outstanding borrowings under the new credit agreement has been reduced from LIBOR plus 2.25% to LIBOR plus 1.75%. The financial covenants in the new credit agreement are substantially similar to the previous credit agreement. (continues)
1) When is the last time TGX raised cash through an offering (diluted)?
We haven’t raised any cash since 2nd IPO in 1989
2) How much cash (not cash equivalents) does TGX have?
We report cash and cash equivalents and our 3rd quarter cash and equivalents (at September 30) will be shown in the 10-Q which will be issued by the middle of November. SEC filings can be found on our website www.theragenics.com in the Investor Relations section or the SEC’s website.
3) What and approximately when is the next known catalyst?
We will have an earnings call, most likely the week of 11/8, if you would like to listen in to hear management speak on strategy and the marketplace.
4) What is TGX's quarterly cash burn?
Our 3rd quarter earnings release, 10Q with cash flow statement should provide insight on cash used.
5) Does TGX have an existing line of credit and if so how much can they draw against it?
We just renewed our line of credit, press release is below.
PRESS RELEASE: Theragenics(R) Renews Credit Agreement
(Dow Jones and Company, Inc.) Oct 11 07:16 AM EDT
Available Borrowings Increased to $40 Million Under Amended and Restated Credit Agreement BUFORD, Ga.--(BUSINESS WIRE)--October 11, 2012--
Theragenics Corporation (NYSE: TGX), a medical device company serving the surgical products and prostate cancer treatment markets, today announced that it has entered into a Second Amended and Restated Credit Agreement with Wells Fargo Bank, National Association. The new three year credit agreement, which is unsecured, replaces the $30 million credit agreement with Wells Fargo that was set to expire on October 31, 2012. Borrowings of$22 million that were outstanding under the old credit agreement have been refinanced under the new $ 40 million credit agreement. The interest rate on outstanding borrowings under the new credit agreement has been reduced from LIBOR plus 2.25% to LIBOR plus 1.75%. The financial covenants in the new credit agreement are substantially similar to the previous credit agreement. (continues)